New contender emerges in the battle against obesity
NCT ID NCT07150975
Summary
This study aims to see if a new injectable medication called GZR18 works as well or better than the approved drug Wegovy (semaglutide) for weight loss. It will involve 420 adults who are overweight or have obesity, with or without type 2 diabetes. Participants will receive one of the two injections for 52 weeks to compare changes in body weight and other health measures.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY/OVERWEIGHT IN ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.